SILVERARC CAPITAL MANAGEMENT, LLC

Position in ERAS — Erasca, Inc.

CIK 1816307 BOSTON, MA

Position in ERAS

as of Mar 31, 2026 · filed May 14, 2026 Compact

Position Value

$29,962,318

+$25,060,906 QoQ

Shares Held

1,851,812

+40.5% QoQ

Ownership

0.595%

of shares outstanding

% of Portfolio

3.54%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Sep 2021

10 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

SILVERARC CAPITAL MANAGEMENT, LLC holds $782,503,784 across 55 Biotechnology names. ERAS ranks #10 (3.8% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	KALV	KalVista Pharmaceuticals, Inc.	2,876,407	$57,902,072
2	DNTH	Dianthus Therapeutics, Inc. /DE/	654,746	$54,946,284
3	COGT	Cogent Biosciences, Inc.	1,314,189	$50,583,134
4	CELC	Celcuity Inc.	357,903	$40,851,048
5	IMNM	Immunome Inc.	1,850,278	$40,465,579
6	KOD	Kodiak Sciences Inc.	991,930	$37,812,371
7	NUVL	Nuvalent, Inc.	354,914	$36,360,939
8	ABVX	Abivax S.A.	302,530	$33,686,715

10 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$29,962,318	1,851,812	+40.5%	Shares	Sole	2026-05-14
2025-12-31	$4,901,412	1,317,584	-3.7%	Shares	Sole	2026-02-12
2025-09-30	$2,982,403	1,368,075	-46.8%	Shares	Sole	2025-11-12
2025-06-30	$3,263,380	2,569,591	-65.1%	Shares	Sole	2025-08-14
2025-03-31	$10,094,154	7,367,996	-2.3%	Shares	Sole	2025-05-14
2024-12-31	$18,935,191	7,543,901	+8.6%	Shares	Sole	2025-02-14
2024-09-30	$18,963,912	6,946,488	-11.1%	Shares	Sole	2024-11-14
2024-06-30	$18,447,945	7,816,926	+3392.1%	Shares	Sole	2024-08-14
2024-03-31	$461,120	223,845	+140.4%	Shares	Sole	2024-05-15
2021-09-30	$1,976,048	93,122	—	Shares	Sole	2021-11-15
No filing history on record for this holder in this stock.